Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pancreatic Digestive Enzyme LipaCreon Approved: Abbott Japan, Eisai
May 16, 2011
- Legal Prescription Receipt Rate Exceeds 65%: JPA
May 16, 2011
- Production to Resume at Takahagi Tech Center in Oct.: Astellas
May 16, 2011
- Tramcet Combination Tab Approved for Relief of Chronic Pain: Janssen
May 16, 2011
- Industry Concerned About Possibility of Consecutive NHI Price Revisions
May 16, 2011
- Takara Bio Aims for Sales of ¥22,700 Mil. in FY2013
May 16, 2011
- Suprane Approved for Inhalation Anesthesia: Baxter
May 16, 2011
- Taiyo Reportedly Seeking Strategic Alliance with Teva
May 16, 2011
- Alfresa HD Revises Profit Forecasts Downward Due to Losses Caused by Quake
May 16, 2011
- Genzyme's Thymoglobulin Obtains Additional Indication
May 16, 2011
- DSP, CiRA to Jointly Develop Drugs for a Rare, Intractable Disease
May 16, 2011
- MatsumotoKiyoshi HD Maintains “A-”Rating: R&I
May 16, 2011
- New Dosage Approved for Shionogi's Finibax
May 16, 2011
- Astellas Announces Changes in Top Leadership
May 16, 2011
- Assessing Contamination Risk Important in Wake of Nuclear Accident: Mr Igari of JPMA
May 16, 2011
- Takeda Submits 2 sNDAs for Velcade in the US
May 16, 2011
- Expectations High for BI Japan's Prazaxa, 1st Novel Oral Anticoagulant in Half a Century
May 16, 2011
- Japan Is Best Positioned to Help China Strengthen Its New Drug Development Capability: Mr Hasegawa
May 16, 2011
- Chugai Files for Add'l Indication for Herceptin Based in Info in Public Domain
May 16, 2011
- MSs from Wholesalers Provide Valuable Services in Emergency, MRs Feel Small
May 16, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…